22 results
8-K
EX-99.1
ALBT
Avalon GloboCare Corp
16 Jun 23
Entry into a Material Definitive Agreement
4:08pm
subsequent to the date of this presentation . Forward - Looking Statements
3 Nasdaq: ALBT Mission: Avalon GloboCare Corp. (Nasdaq: ALBT
8-K
EX-99.1
ALBT
Avalon GloboCare Corp
2 May 22
Regulation FD Disclosure
4:00pm
date subsequent to the date of this presentation . Forward - Looking Statements
Mission: Avalon GloboCare Corp. (Nasdaq: AVCO) is a clinical - stage
8-K
EX-99.1
ALBT
Avalon GloboCare Corp
14 Jun 21
Avalon GloboCare Announces Execution of Purchase Agreement for Acquisition of SenlangBio in All Stock Transaction
9:12am
equity-linked or debt instruments will be issued in connection with the transaction.
The transaction is aligned with Avalon’s mission of developing next
DEFA14A
EX-99.1
ALBT
Avalon GloboCare Corp
14 Jun 21
Additional proxy soliciting materials
9:10am
equity-linked or debt instruments will be issued in connection with the transaction.
The transaction is aligned with Avalon’s mission of developing next
424B5
ALBT
Avalon GloboCare Corp
13 Dec 19
Prospectus supplement for primary offering
5:07pm
of pathologies, thus allowing for the introduction of novel non-invasive “liquid biopsies”. Our mission is focused on diagnostic advancements … necessary to enable personalized clinical management. There is no guarantee that we will be able to successfully achieve our stated mission.
We currently
424B2
20glxs80s1t3luboq
26 Apr 19
Prospectus for primary offering
5:07pm
S-3/A
saqut
15 Jan 19
Shelf registration (amended)
3:31pm
S-3
nwgxu25fnxtr5l7cje9m
3 Jan 19
Shelf registration
12:00am
8-K
EX-99.1
t5jh2ys1 bx3
14 Nov 18
Reports 30% Increase in Revenues
10:05am
424B4
nvtvk mf7ck
14 Aug 18
Prospectus supplement with pricing info
12:18pm